Stiripentol for the Treatment of Refractory Status Epilepticus

NCT ID: NCT06540378

Last Updated: 2024-08-06

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 25 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-01-01
• Study Completion Date: 2024-05-31

Brief Summary

The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who received additional treatment of SE with STP. All patients who received STP during the SE were included, regardless of previous medication.

Detailed Description

The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology, University Hospital Marburg, Germany, between 2013 and 2023 with a diagnosis of status epilepticus, who received additional treatment of SE with STP. They were able to identify 25 patients who received STP as add on therapy. All these patients suffered from RSE or SRSE. Since there was no SOP or treatment algorithm available, they have listed the individual treatment regimens in Table 2. 5 of these patients were previously published in a case series (Strzelczyk et al. 2015).

Treatment success was defined as continuous interruption of the SE. Descriptive statistics are reported as absolute numbers and percentages, mean ± standard deviation (SD) or median ± median absolute deviation.

The study was approved by the local IRB.

Conditions

Status Epilepticus

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

STP in RSE or SRSE

Patients received additional treatment of SE with STP

Stiripentol

Intervention Type: DRUG

Interventions

Stiripentol

Intervention Type: DRUG

Other Intervention Names

Diacomit

Eligibility Criteria

Inclusion Criteria

• adult patients who suffered from RSE or SRSE and received STP as add on therapy.

Exclusion Criteria

• children

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital Marburg

OTHER

Sponsor Role: lead

Responsible Party

Leona Möller

Leona Möller, MD; Principal Investigator, Consultant in Neurology

Responsibility Role: PRINCIPAL_INVESTIGATOR

References

Moller L, Simon OJ, Junemann C, Austermann-Menche M, Bergmann MP, Habermehl L, Menzler K, Timmermann L, Strzelczyk A, Knake S. Stiripentol for the treatment of refractory status epilepticus. Neurol Res Pract. 2024 Oct 21;6(1):49. doi: 10.1186/s42466-024-00348-x.

Reference Type: DERIVED

PMID: 39428490 (View on PubMed)

Other Identifiers

24-61 RS

Identifier Type: -

Identifier Source: org_study_id